title: In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia.
abstract: We tested the MICs of fusidic acid (CEM-102) plus other agents against 40 methicillin-resistant Staphylococcus aureus (MRSA) isolates from cystic fibrosis patients and the activities of fusidic acid with or without tobramycin or amikacin against Pseudomonas aeruginosa, MRSA, and Burkholderia cepacia isolates from cystic fibrosis patients in a 24-h time-kill study. Fusidic acid was potent (MICs, 0.125 to 0.5 μg/ml; a single 500-mg dose of fusidic acid at 8 h averaged 8 to 12. 5 μg/ml with 91 to 97% protein binding) against all MRSA strains. No antagonism was observed; synergy occurred for one MRSA strain treated with fusidic acid plus tobramycin.
authors.affiliation: Department of Pathology, Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA.
authors.forename: Pamela
authors.initials: P
authors.lastname: McGhee
authors.forename: Catherine
authors.initials: C
authors.lastname: Clark
authors.forename: Kim
authors.initials: K
authors.lastname: Credito
authors.forename: Linda
authors.initials: L
authors.lastname: Beachel
authors.forename: Glenn A
authors.initials: GA
authors.lastname: Pankuch
authors.forename: Peter C
authors.initials: PC
authors.lastname: Appelbaum
authors.forename: Klaudia
authors.initials: K
authors.lastname: Kosowska-Shick
mesh_terms: D000583:Amikacin / Q000494:pharmacology*; D016956:Burkholderia cepacia / Q000187:drug effects*; D003550:Cystic Fibrosis / Q000382:microbiology*; D004357:Drug Synergism; D005672:Fusidic Acid / Q000494:pharmacology*; D006801:Humans; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D013211:Staphylococcus aureus / Q000187:drug effects*; D014031:Tobramycin / Q000494:pharmacology*
chemical_list: D005672:Fusidic Acid; D000583:Amikacin; D014031:Tobramycin